In 2023, Yu et al. (Yu et al. 2023) reported the discovery of a highly potent and selective macrocyclic CDK2 inhibitor via generative models and structure‐based drug design that showed robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration. This evidence concerns the gene CDK2 and ovarian carcinoma.